A citation-based method for searching scientific literature


List of co-cited articles
53 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A plugin for the Ensembl Variant Effect Predictor that uses MaxEntScan to predict variant spliceogenicity.
Jannah Shamsani, Stephen H Kazakoff, Irina M Armean, Will McLaren, Michael T Parsons, Bryony A Thompson, Tracy A O'Mara, Sarah E Hunt, Nicola Waddell, Amanda B Spurdle. Bioinformatics 2019
23
75


Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.
Barbara Rivera, Massimo Di Iorio, Jessica Frankum, Javad Nadaf, Somayyeh Fahiminiya, Suzanna L Arcand, David L Burk, Damien Grapton, Eva Tomiak, Valerie Hastings,[...]. Cancer Res 2017
19
75

The mutational constraint spectrum quantified from variation in 141,456 humans.
Konrad J Karczewski, Laurent C Francioli, Grace Tiao, Beryl B Cummings, Jessica Alföldi, Qingbo Wang, Ryan L Collins, Kristen M Laricchia, Andrea Ganna, Daniel P Birnbaum,[...]. Nature 2020
50

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
985
50

Reference-based phasing using the Haplotype Reference Consortium panel.
Po-Ru Loh, Petr Danecek, Pier Francesco Palamara, Christian Fuchsberger, Yakir A Reshef, Hilary K Finucane, Sebastian Schoenherr, Lukas Forer, Shane McCarthy, Goncalo R Abecasis,[...]. Nat Genet 2016
607
50

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
923
50

High-throughput carrier screening using TaqMan allelic discrimination.
Anastasia Fedick, Jing Su, Chaim Jalas, Lesley Northrop, Batsal Devkota, Josef Ekstein, Nathan R Treff. PLoS One 2013
18
50

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
50

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
Marc Tischkowitz, Nelly Sabbaghian, Nancy Hamel, Carly Pouchet, William D Foulkes, Anne-Marie Mes-Masson, Diane M Provencher, Patricia N Tonin. BMC Med Genet 2013
16
50

ClinVar: improving access to variant interpretations and supporting evidence.
Melissa J Landrum, Jennifer M Lee, Mark Benson, Garth R Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, Jennifer Hart, Douglas Hoffman, Wonhee Jang,[...]. Nucleic Acids Res 2018
50

Cohort profile of the CARTaGENE study: Quebec's population-based biobank for public health and personalized genomics.
Philip Awadalla, Catherine Boileau, Yves Payette, Youssef Idaghdour, Jean-Philippe Goulet, Bartha Knoppers, Pavel Hamet, Claude Laberge. Int J Epidemiol 2013
114
50

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
339
50

CADD: predicting the deleteriousness of variants throughout the human genome.
Philipp Rentzsch, Daniela Witten, Gregory M Cooper, Jay Shendure, Martin Kircher. Nucleic Acids Res 2019
50

Identifying a high fraction of the human genome to be under selective constraint using GERP++.
Eugene V Davydov, David L Goode, Marina Sirota, Gregory M Cooper, Arend Sidow, Serafim Batzoglou. PLoS Comput Biol 2010
970
50

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
P N Tonin, A M Mes-Masson, P A Futreal, K Morgan, M Mahon, W D Foulkes, D E Cole, D Provencher, P Ghadirian, S A Narod. Am J Hum Genet 1998
130
50

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Melissa S Cline, Rachel G Liao, Michael T Parsons, Benedict Paten, Faisal Alquaddoomi, Antonis Antoniou, Samantha Baxter, Larry Brody, Robert Cook-Deegan, Amy Coffin,[...]. PLoS Genet 2018
86
50

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.
William D Foulkes, Parviz Ghadirian, Mohammed Reza Akbari, Nancy Hamel, Sylvie Giroux, Nelly Sabbaghian, Andrew Darnel, Robert Royer, Aletta Poll, Eve Fafard,[...]. Breast Cancer Res 2007
107
50

Pathology update to the Manchester Scoring System based on testing in over 4000 families.
D Gareth Evans, Elaine F Harkness, Inga Plaskocinska, Andrew J Wallace, Tara Clancy, Emma R Woodward, Tony A Howell, Marc Tischkowitz, Fiona Lalloo. J Med Genet 2017
36
50

Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.
D J Osher, K De Leeneer, G Michils, N Hamel, E Tomiak, B Poppe, K Leunen, E Legius, A Shuen, E Smith,[...]. Br J Cancer 2012
29
50

REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.
Nilah M Ioannidis, Joseph H Rothstein, Vikas Pejaver, Sumit Middha, Shannon K McDonnell, Saurabh Baheti, Anthony Musolf, Qing Li, Emily Holzinger, Danielle Karyadi,[...]. Am J Hum Genet 2016
692
50

Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.
Chengliang Dong, Peng Wei, Xueqiu Jian, Richard Gibbs, Eric Boerwinkle, Kai Wang, Xiaoming Liu. Hum Mol Genet 2015
585
50

In silico prediction of splice-altering single nucleotide variants in the human genome.
Xueqiu Jian, Eric Boerwinkle, Xiaoming Liu. Nucleic Acids Res 2014
244
50

Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
Kathleen K Oros, Parviz Ghadirian, Celia M T Greenwood, Chantal Perret, Zhen Shen, Yosabeth Paredes, Suzanna L Arcand, Anne-Marie Mes-Masson, Steven A Narod, William D Foulkes,[...]. Int J Cancer 2004
35
50

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
409
50


Population history and its impact on medical genetics in Quebec.
A-M Laberge, J Michaud, A Richter, E Lemyre, M Lambert, B Brais, G A Mitchell. Clin Genet 2005
138
50

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
50


A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
Amélie Rodrigue, Guillaume Margaillan, Thiago Torres Gomes, Yan Coulombe, Gemma Montalban, Simone da Costa E Silva Carvalho, Larissa Milano, Mandy Ducy, Giuliana De-Gregoriis, Graham Dellaire,[...]. Nucleic Acids Res 2019
25
50

Human genetics: lessons from Quebec populations.
C R Scriver. Annu Rev Genomics Hum Genet 2001
115
50

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Xin Yang, Honglin Song, Goska Leslie, Christoph Engel, Eric Hahnen, Bernd Auber, Judit Horváth, Karin Kast, Dieter Niederacher, Clare Turnbull,[...]. J Natl Cancer Inst 2020
54
50

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
P N Tonin, A M Mes-Masson, S A Narod, P Ghadirian, D Provencher. Clin Genet 1999
46
50

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
185
50

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Moria H Belanger, Lena Dolman, Suzanna L Arcand, Zhen Shen, George Chong, Anne-Marie Mes-Masson, Diane Provencher, Patricia N Tonin. J Ovarian Res 2015
29
50


Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Luca Cavallone, Suzanna L Arcand, Christine M Maugard, Serge Nolet, Louis A Gaboury, Anne-Marie Mes-Masson, Parviz Ghadirian, Diane Provencher, Patricia N Tonin. Fam Cancer 2010
19
50

Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.
Lorelei A Mucci, Jacob B Hjelmborg, Jennifer R Harris, Kamila Czene, David J Havelick, Thomas Scheike, Rebecca E Graff, Klaus Holst, Sören Möller, Robert H Unger,[...]. JAMA 2016
378
50

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
881
50

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
678
50

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Alfons Meindl, Heide Hellebrand, Constanze Wiek, Verena Erven, Barbara Wappenschmidt, Dieter Niederacher, Marcel Freund, Peter Lichtner, Linda Hartmann, Heiner Schaal,[...]. Nat Genet 2010
476
50

Nonsense-mediated mRNA decay in humans at a glance.
Tatsuaki Kurosaki, Lynne E Maquat. J Cell Sci 2016
218
50


NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Mary B Daly, Robert Pilarski, Matthew B Yurgelun, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Judy E Garber,[...]. J Natl Compr Canc Netw 2020
175
50

Effective variant filtering and expected candidate variant yield in studies of rare human disease.
Brent S Pedersen, Joe M Brown, Harriet Dashnow, Amelia D Wallace, Matt Velinder, Martin Tristani-Firouzi, Joshua D Schiffman, Tatiana Tvrdik, Rong Mao, D Hunter Best,[...]. NPJ Genom Med 2021
12
50

Hereditary breast and ovarian cancer: new genes in confined pathways.
Finn Cilius Nielsen, Thomas van Overeem Hansen, Claus Storgaard Sørensen. Nat Rev Cancer 2016
205
50

Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer.
Marina Pavanello, Isaac Hy Chan, Amir Ariff, Paul Dp Pharoah, Simon A Gayther, Susan J Ramus. Cancers (Basel) 2020
10
50

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
50

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
50

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.